Table 8.
Sensitivity Analysis II: Subgroup Analysis by Different Doses of Alteplase
| Characteristics | AF | Non‐AF | After IPTW | Interaction† | |||
|---|---|---|---|---|---|---|---|
| RR (95% CI) | P value | Adjusted RR ‡ (95% CI) | P value | ||||
| Low dose of 0.6 mg/kg subgroup, N=381 | |||||||
| mRS of 0–1 | 23.4% (44/188) | 34.2% (66/193) | 0.98 (0.83–1.16) | 0.8194 | 0.96 (0.81–1.14) | 0.6473 | 0.1829 |
| mRS of 0–2 | 33.5% (63/188) | 47.7% (92/193) | 0.91 (0.75–1.09) | 0.2954 | 0.91 (0.75–1.10) | 0.3359 | 0.1620 |
| SICH at 24–36 h | |||||||
| By NINDS standard | 5.9% (11/188) | 2.1% (4/193) | 2.36 (1.04–5.34) | 0.0400 * | 2.63 (1.10–6.32) | 0.0302 * | 0.0009 * |
| By ECASS II standard | 3.7% (7/188) | 1.6% (3/193) | 2.04 (0.76–5.47) | 0.1560 | 2.52 (0.86–7.43) | 0.0927 | 0.3505 |
| By SITS‐MOST standard | 1.6% (3/188) | 0.5% (1/193) | 4.37 (0.64–29.84) | 0.1323 | 4.49 (0.64–31.58) | 0.1313 | 0.8338 |
| Standard dose of 0.9 mg/kg subgroup, N=682 | |||||||
| mRS of 0–1 | 33.8% (79/234) | 37.1% (166/448) | 0.91 (0.79–1.04) | 0.1619 | 1.05 (0.91–1.20) | 0.5198 | |
| mRS of 0–2 | 46.2% (108/234) | 52.5% (213/448) | 0.85 (0.73–0.96) | 0.0315 * | 1.09 (0.94–1.27) | 0.2353 | |
| SICH at 24–36 h | |||||||
| By NINDS standard | 4.7% (11/234) | 3.3% (15/448) | 1.23 (0.71–2.11) | 0.4587 | 1.66 (0.92–3.01) | 0.0917 | |
| By ECASS II standard | 2.6% (6/234) | 1.8% (8/448) | 1.21 (0.57–2.58) | 0.6190 | 1.32 (0.57–3.05) | 0.5149 | |
| By SITS‐MOST standard | 1.3% (3/234) | 1.1% (5/448) | 1.07 (0.39–2.96) | 0.8892 | 1.42 (0.47–4.34) | 0.5359 | |
AF indicates atrial fibrillation; ECASS II, European Cooperative Acute Stroke Study II; IPTW, inverse probability of treatment weighting; mRS, modified Rankin Scale; NINDS, National Institute of Neurological Disorders and Stroke; RR, relative risk; SICH, symptomatic intracranial hemorrhage; and SITS‐MOST, Safe Implementation of Thrombolysis in Stroke‐Monitoring Study.
The interaction term was between AF status and alteplase dose.
Statistically significant at P<0.05.
Multivariable Poisson regression was adjusted for fixed effects of the THRIVE (Totaled Health Risks in Vascular Events) score, prestroke mRS, early ischemic changes, and use of antithrombotic medications, and random effects for 30 hospitals.